Monika Roy1, Charles Holmes2,3, Izukanji Sikazwe2, Thea Savory2, Mwanza Wa Mwanza2, Carolyn Bolton Moore2,4, Kafula Mulenga2, Nancy Czaicki1, David V Glidden5, Nancy Padian6, Elvin Geng1. 1. Division of HIV/AIDS, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco General Hospital. 2. Centre for Infectious Diseases Research in Zambia, Lusaka. 3. Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. University of Alabama, Birmingham. 5. Department of Epidemiology and Biostatistics, University of California, San Francisco. 6. Division of Epidemiology, University of California Berkeley.
Abstract
Background: Differentiated service delivery (DSD) for human immunodeficiency virus (HIV)-infected persons who are clinically stable on antiretroviral therapy (ART) has been embraced as a solution to decrease access barriers and improve quality of care. However, successful DSD implementation is dependent on understanding the prevalence, incidence, and durability of clinical stability. Methods: We evaluated visit data in a cohort of HIV-infected adults who made at least 1 visit between 1 March 2013 and 28 February 2015 at 56 clinics in Zambia. We described visit frequency and appointment intervals using conventional stability criteria and used a mixed-effects linear regression model to identify predictors of appointment interval. We developed a multistate model to characterize patient stability over time and calculated incidence rates for transition between states. Results: Overall, 167819 patients made 3418018 post-ART initiation visits between 2004 and 2015. Fifty-four percent of visits were pharmacy refill-only visits, and 24% occurred among patients on ART for >6 months and whose current CD4 was >500 cells/mm3. Median appointment interval at clinician visits was 59 days, and time on ART and current CD4 were not strong predictors of appointment interval. Cumulative incidence of clinical stability was 66.2% at 2 years after enrollment, but transition to instability (31 events per 100 person-years) and lapses in care (41 events per100 person-years) were common. Conclusions: Current facility-based care was characterized by high visit burden due to pharmacy refills and among treatment-experienced patients. Differentiated service delivery models targeted toward stable patients need to be adaptive given that clinical stability was highly transient and lapses in care were common.
Background: Differentiated service delivery (DSD) for human immunodeficiency virus (HIV)-infectedpersons who are clinically stable on antiretroviral therapy (ART) has been embraced as a solution to decrease access barriers and improve quality of care. However, successful DSD implementation is dependent on understanding the prevalence, incidence, and durability of clinical stability. Methods: We evaluated visit data in a cohort of HIV-infected adults who made at least 1 visit between 1 March 2013 and 28 February 2015 at 56 clinics in Zambia. We described visit frequency and appointment intervals using conventional stability criteria and used a mixed-effects linear regression model to identify predictors of appointment interval. We developed a multistate model to characterize patient stability over time and calculated incidence rates for transition between states. Results: Overall, 167819 patients made 3418018 post-ART initiation visits between 2004 and 2015. Fifty-four percent of visits were pharmacy refill-only visits, and 24% occurred among patients on ART for >6 months and whose current CD4 was >500 cells/mm3. Median appointment interval at clinician visits was 59 days, and time on ART and current CD4 were not strong predictors of appointment interval. Cumulative incidence of clinical stability was 66.2% at 2 years after enrollment, but transition to instability (31 events per 100 person-years) and lapses in care (41 events per100 person-years) were common. Conclusions: Current facility-based care was characterized by high visit burden due to pharmacy refills and among treatment-experienced patients. Differentiated service delivery models targeted toward stable patients need to be adaptive given that clinical stability was highly transient and lapses in care were common.
Authors: Freya Rasschaert; Barbara Telfer; Faustino Lessitala; Tom Decroo; Daniel Remartinez; Marc Biot; Baltazar Candrinho; Francisco Mbofana; Wim Van Damme Journal: PLoS One Date: 2014-03-20 Impact factor: 3.240
Authors: John A Naslund; Jodie Dionne-Odom; Cléonas Junior Destiné; Kristen M Jogerst; Redouin Renold Sénécharles; Michelande Jean Louis; Jasmin Desir; Yvette Néptune Ledan; Jude Ronald Beauséjour; Roland Charles; Alice Werbel; Elizabeth A Talbot; Patrice Joseph; Jean William Pape; Peter F Wright Journal: AIDS Res Treat Date: 2014-12-07
Authors: Freya Rasschaert; Tom Decroo; Daniel Remartinez; Barbara Telfer; Faustino Lessitala; Marc Biot; Baltazar Candrinho; Wim Van Damme Journal: J Int AIDS Soc Date: 2014-10-06 Impact factor: 5.396
Authors: Florian Vogt; Lucien Kalenga; Jean Lukela; Freddy Salumu; Ibrahim Diallo; Elena Nico; Emmanuel Lampart; Rafael Van den Bergh; Safieh Shah; Olumide Ogundahunsi; Rony Zachariah; Johan Van Griensven Journal: J Acquir Immune Defic Syndr Date: 2017-03-01 Impact factor: 3.731
Authors: Elizabeth A McCarthy; Hamsa L Subramaniam; Margaret L Prust; Marta R Prescott; Felton Mpasela; Albert Mwango; Leah Namonje; Crispin Moyo; Benjamin Chibuye; Jan Willem van den Broek; Lindsey Hehman; Sarah Moberley Journal: PLoS One Date: 2017-04-18 Impact factor: 3.240
Authors: Shabbar Jaffar; Barbara Amuron; Susan Foster; Josephine Birungi; Jonathan Levin; Geoffrey Namara; Christine Nabiryo; Nicaise Ndembi; Rosette Kyomuhangi; Alex Opio; Rebecca Bunnell; Jordan W Tappero; Jonathan Mermin; Alex Coutinho; Heiner Grosskurth Journal: Lancet Date: 2009-11-24 Impact factor: 79.321
Authors: Andreas D Haas; Leigh F Johnson; Anna Grimsrud; Nathan Ford; Catarina Mugglin; Matthew P Fox; Jonathan Euvrard; Monique van Lettow; Hans Prozesky; Izukanji Sikazwe; Cleophas Chimbetete; Michael Hobbins; Cordelia Kunzekwenyika; Matthias Egger Journal: J Acquir Immune Defic Syndr Date: 2019-08-01 Impact factor: 3.731